# Phase 2 infections trials recruiting: 100 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 100 trials in phase 2 for infections that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 infections trials: 100 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/infections

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 100
- Recruiting or not yet: 100
- Read on: November 19, 2026

## Trials

The 25 newest of 100, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 20, 2026 | NCT07881991 | Phase 2 Study of SYH2066 Tablets Compared With Placebo in Chinese Adult Patients With Respiratory Syncytial Virus Infection. | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Respiratory Syncytial Virus Infections | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881991) |
| October 7, 2026 | NCT07862569 | DOR/ISL in Pediatric Participants With HIV-1, \<18 Years of Age and ≥ 35 kg | Merck Sharp & Dohme LLC | Phase 2 | Not yet recruiting | HIV-1, HIV Infection | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862569) |
| September 11, 2026 | NCT07816250 | A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY) | ViiV Healthcare | Phase 2 | Not yet recruiting | HIV Infections | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816250) |
| September 9, 2026 | NCT07808697 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to \<12 Years of Age | ModernaTX, Inc. | Phase 2 | Recruiting | SARS-CoV-2 | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808697) |
| August 28, 2026 | NCT07792915 | A Clinical Trial of Resistant Potato Starch for Gut MDRO Decolonization | VA Office of Research and Development | Phase 2 | Not yet recruiting | Clostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA), Vancomycin-Resistant Enterococci... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07792915) |
| August 11, 2026 | NCT07756840 | Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP) | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV), Papillomavirus Infection, Laryngeal Diseases... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07756840) |
| July 17, 2026 | NCT07712484 | A Phase II Randomized Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated... | F2G Ltd | Phase 2 | Not yet recruiting | Coccidioidomycosis, Disseminated Fungal Infection, Coccidioides Infection, Coccidioides Immitis Infection, Coccidioides... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07712484) |
| July 15, 2026 | NCT07704164 | Colchicine to Reduce Coronary Artery Inflammation in People With HIV | Instituto de Investigación Hospital Universitario La Paz | Phase 2 | Recruiting | HIV Infection, Cardiovascular Diseases (CVD) | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07704164) |
| July 13, 2026 | NCT07698886 | Treatment of Recurrent Genital Warts by Combination of CO2 Laser and Geniwa Gel | KTH Biopharma | Phase 2 | Recruiting | HPV (Human Papillomavirus)-Associated, Genital Warts | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07698886) |
| July 13, 2026 | NCT07697937 | YH02 Injection for Intra-tumor Injection Therapy in Advanced Solid Tumors With Unresponsive or Failure-Treated Cases | Tianjin First Central Hospital | Phase 2 | Recruiting | Advanced Malignant Solid Tumor | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07697937) |
| June 25, 2026 | NCT07669363 | Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions... | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Not yet recruiting | Cervical Intraepithelial Neoplasia, Papillomavirus Infections | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07669363) |
| June 17, 2026 | NCT07654283 | Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions | AusperBio Therapeutics Inc. | Phase 2 | Recruiting | Hepatitis B, Chronic | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07654283) |
| May 19, 2026 | NCT07595042 | A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB) | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Not yet recruiting | Tuberculosis | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07595042) |
| May 7, 2026 | NCT07572396 | Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities | Amplexd Therapeutics, Inc. | Phase 2 | Recruiting | High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion, ASC-US, HPV Infection, Cervical... | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07572396) |
| May 4, 2026 | NCT07565506 | Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU | Lakewood-Amedex Inc | Phase 2 | Recruiting | Diabetic Foot Ulcers (DFUs) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07565506) |
| April 29, 2026 | NCT07555431 | Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection | Sponsor not shown (see the record) | Phase 2 | Recruiting | HTLV-1 Infection, HTLV I Associated Myelopathies, HTLV I Associated T Cell Leukemia Lymphoma, Neuritis | 146 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555431) |
| April 24, 2026 | NCT07550595 | Oritavancin for Treatment of Serious Cardiac Infections | Kirby Institute | Phase 2 | Not yet recruiting | Infective Endocarditis, Cardiac Device Infection, Gram-positive Bacterial Infections | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07550595) |
| April 23, 2026 | NCT07547813 | A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa | Almirall, S.A. | Phase 2 | Recruiting | Hidradenitis Suppurativa | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07547813) |
| April 22, 2026 | NCT07545746 | Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya | UNC Lineberger Comprehensive Cancer Center | Phase 2 | Not yet recruiting | HIV Infections, HPV Infection, Cervix Cancer, CIN2, CIN3, CIN1, CIN, Cervical Intraepithelial Neoplasia Grade 3... | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07545746) |
| April 7, 2026 | NCT07513623 | Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II | University of California, San Francisco | Phase 2 | Not yet recruiting | Cytomegalovirus (CMV), Anterior Uveitis, Infectious Uveitis, CMV Infection | 117 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07513623) |
| March 20, 2026 | NCT07485010 | Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary... | The University of Queensland | Phase 2 | Not yet recruiting | Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM)... | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07485010) |
| March 19, 2026 | NCT07482657 | A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With... | Enanta Pharmaceuticals, Inc | Phase 2 | Recruiting | RSV Infection, RSV, Respiratory Syncytial Virus (RSV) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07482657) |
| March 19, 2026 | NCT07481539 | Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment | Azienda Sanitaria Universitaria Friuli Centrale | Phase 2 | Recruiting | Bacteria Infection, Piperacillin, Tazobactam Drug Combination | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07481539) |
| February 24, 2026 | NCT07431307 | Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With... | BioVersys AG | Phase 2 | Not yet recruiting | Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP), Blood Stream Infection... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07431307) |
| February 18, 2026 | NCT07418034 | A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary... | University of Maryland, Baltimore | Phase 2 | Recruiting | Head and Neck Cancer, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal... | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07418034) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 4 |
| University Hospital, Basel, Switzerland | 3 |
| New York Medical College | 3 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 2 |
| [ViiV Healthcare](https://specstream.ai/data/clinical-trials/company/viiv-healthcare) | 2 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Frantz Viral Therapeutics, LLC | 2 |
| The University of Queensland | 2 |
| Medical University of Vienna | 2 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 2 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2 |
| ANRS, Emerging Infectious Diseases | 2 |
| AusperBio Therapeutics Inc. | 2 |
| Emory University | 2 |
| Amplexd Therapeutics, Inc. | 1 |
| University of Maryland, Baltimore | 1 |
| Locus Biosciences | 1 |
| Sun Yat-sen University | 1 |
| PENTA Foundation | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| Azienda Sanitaria Universitaria Friuli Centrale | 1 |
| Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 1 |
| [Shionogi](https://specstream.ai/data/clinical-trials/company/shionogi) | 1 |
| University of California, San Francisco | 1 |
| Instituto de Investigación Hospital Universitario La Paz | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 43 |
| China | 11 |
| Spain | 9 |
| Australia | 8 |
| France | 7 |
| Canada | 6 |
| Italy | 6 |
| Taiwan | 6 |
| Argentina | 5 |
| Poland | 5 |
| United Kingdom | 5 |
| Japan | 4 |
| Thailand | 4 |
| Vietnam | 4 |
| Denmark | 4 |
| Greece | 4 |
| Switzerland | 3 |
| Belgium | 3 |
| Germany | 3 |
| South Korea | 3 |
| Bulgaria | 3 |
| Brazil | 3 |
| India | 3 |
| Mexico | 3 |
| Hungary | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Commercial real estate firms in the United States](https://specstream.ai/data/businesses/commercial-real-estate-firms/united-states)
- [Osteopathic practices in the United States](https://specstream.ai/data/businesses/osteopathic-practices/united-states)
- [B2B secretarial companies in the United States](https://specstream.ai/data/businesses/b2b-secretarial-companies/united-states)
- [Jewelry and watches manufacturers in the United States](https://specstream.ai/data/businesses/jewelry-and-watches-manufacturers/united-states)
- [Water utilities in the United States](https://specstream.ai/data/businesses/water-utilities/united-states)
- [French restaurants in the United States](https://specstream.ai/data/businesses/french-restaurants/united-states)
